Form 10-Q TANDEM DIABETES CARE For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Tandem Diabetes Care (TNDM) PT Raised to $9 at Cowen; More Upside
April 27, 2018 7:48 AM EDTCowen raised its price target on Tandem Diabetes Care (NASDAQ: TNDM) to $9.00 (from $7.00) while maintaining a Outperform rating.
Analyst Doug Schenkel commented, "TNDM posted a solid Q1 beat. We expect numerous revenue growth catalysts (new products, renewals, Animas, international, infusion sets) to drive upside to... More
